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Abstract:  32 
The present study aimed to compare the efficacy of a porcine circovirus type 2 33 
(PCV2) commercial vaccine in terms of average daily weight gain (ADWG) as well as 34 
infection dynamics in pigs with different maternally derived antibody (MDA) levels. A total 35 
of 337 animals from a PCV2 subclinically infected farm were distributed into two groups 36 
based on weight and PCV2 antibody levels (high [H] or low [L]) at 2 weeks of age. One 37 
week later, these animals were subdivided in four groups according to the treatment 38 
received. Vaccinated pigs (H-V and L-V) received 1 mL of a commercial vaccine and NV 39 
(H-NV and L-NV) received 1 mL of PBS. All piglets were subsequently bled at 7, 12, 18, 40 
22 and 25 weeks of age and weighted at 12 and 25 weeks of age. V animals showed 41 
significantly lower PCV2 infection rates and viral load as well as higher ELISA S/P ratios 42 
and ADWG than NV ones. Compared with H-V piglets, L-V pigs showed numerically 43 
lower PCV2 infection rates, lower area under the curve of viral load, an earlier 44 
seroconversion and a numerically, but not significantly, higher ADWG. In this study, MDA 45 
did not seem to interfere with the effect of PCV2 vaccination on ADWG. However, only 46 
when a small subpopulation of pigs with the highest ELISA S/P ratios at vaccination was 47 
considered, an apparent interference of vaccine efficacy on ADWG was noticed. Therefore, 48 
the impact of the putative interference under field conditions is probably negligible for 49 
most farms. 50 
 51 
Keywords: Interference; Maternally derived antibodies; Overcoming of maternal immunity; 52 
porcine circovirus type 2; Vaccine   53 
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1. Introduction 54 
Porcine circovirus type 2 (PCV2) is the essential causative agent of a series of 55 
diseases known as porcine circovirus diseases (PCVD) [1, 2]. Postweaning multisystemic 56 
wasting syndrome (PMWS), currently denominated as PCV2-systemic disease (PCV2-SD), 57 
is one of the most economically important PCVD, since it increases the mortality rate and 58 
reduces production parameters [1, 3]. The effects derived from PCV2-SD have been 59 
drastically reduced by the use of different available commercial vaccines at the worldwide 60 
swine production market [4].  61 
Besides the contrasted efficacy of PCV2 vaccines, some field and experimental 62 
studies have indicated that vaccination in face of high maternally derived antibody (MDA) 63 
levels may affect such efficacy. This potential interference has been studied at two different 64 
levels: vaccine-elicited humoral immune response and average daily weight gain (ADWG). 65 
In terms of humoral response, it has been proven that high antibody levels at the moment of 66 
vaccination jeopardize the seroconversion elicited by vaccination [5-8]. On the contrary, the 67 
effect of high MDA level on ADWG has only been assessed in three studies [5, 9, 10] in 68 
which the results obtained were not conclusive. In Fachinger et al. [10], animals included in 69 
the study were selected and separated in two groups based on the level of MDA at the 70 
moment of vaccination (>1:1000 and <1:1000 indirect fluorescence antibody [IFA] titres). 71 
Both groups of animals had similar (p>0.05) ADWG and in consequence it was concluded 72 
that this parameter was not affected by MDA level. However, the average titre for both 73 
groups of animals was not provided in the paper, and apparently they were not sharply 74 
different. Similarly, Fraile et al. [5] did not find statistically significant differences in terms 75 
of ADWG between 4-week-old vaccinated piglets derived from vaccinated and non-76 
vaccinated sows. However, the correlation between initial MDA and ADWG (in the double 77 
4 
 
vaccinated ones) showed a negative slope, suggesting a potential negative effect when 78 
higher MDA titres were present at vaccination time. In Haake et al. [9], pigs were 79 
vaccinated at 1 or 3 weeks of age, which rendered different maturity of the immune system 80 
as well as levels of MDA at the moment of vaccination. In that study, animals vaccinated at 81 
3 weeks of age had a higher ADWG than the ones vaccinated at 1 week of age. When 82 
compared, antibody titres of the pigs at 1 week of age were higher than those at 3 weeks of 83 
age.  84 
Based on these inconsistencies, the present study aimed to assess PCV2 vaccination 85 
in terms of ADWG in purposely selected age-matched animals with high and low PCV2 86 
ELISA S/P levels at the time of PCV2 vaccination. In addition, antibody and infection 87 
dynamics as well as viral loads of these animals were studied.  88 
 89 
2. Materials and methods 90 
2.1. Farm selection  91 
The present study was conducted in a conventional Spanish multi-site production 92 
system in which PCV2 vaccination of 3 week-old piglets (Porcilis PCV, MSD) was applied 93 
routinely since 2 years before starting this study. An all-in-all-out management strategy was 94 
used in both nursery and fattening units.  95 
In order to assess PCV2 infection before the start of the study, blood samples from 96 
10 animals of different ages (5, 9, 14, 18 and 24 weeks of age) were taken. These blood 97 
samples were processed by standard PCR [11]. PCV2 genome was detected in 30% (3 out 98 
of 10) and 40% (4 out of 10) of pigs at 14 and 18 weeks of age, respectively. All tested 99 
samples from 5, 9 and 24 weeks of age were negative by PCR. 100 
 101 
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2.2. Study design 102 
To ensure the presence of different levels (from very low to very high) of PCV2 103 
MDA titres at the moment of vaccination, a proportion of sows were vaccinated before 104 
farrowing. Thus, from 64 randomly selected sows, 33 (52%) were vaccinated 105 
intramuscularly (IM) (neck muscle, needle length: 1.2x40 mm) with 1 dose of 2 mL of 106 
Circovac (Merial; batch number L383022) at 3 and 6 weeks pre-farrowing (V sows). The 107 
remaining 31 sows were left non-vaccinated (NV sows).  108 
At 2 weeks of age, all healthy piglets (n=572) born from these 64 sows were ear-109 
tagged, weighted and bled. Levels of PCV2 antibodies were measured by means of an 110 
indirect ELISA (detailed in PCV2 antibody detection section). The ELISA S/P ratios 111 
obtained in these 572 animals ranged from 0.14 to 2.68 (mean ± standard deviation [SD] 112 
=1.25±0.70). From all tested animals and based on the equivalences provided by Pileri et al. 113 
[12], those piglets with the highest (>1.44 or >log2 13 IPMA values, n=169) and the lowest 114 
(<0.96 or <log2 10 IPMA values, n=168) PCV2 ELISA S/P ratios were selected. Animals 115 
with medium (>0.96 and <1.44) PCV2 ELISA S/P ratios were removed from the study. 116 
Afterwards, selected animals were distributed based on their weight in 4 treatments groups 117 
according to the levels of MDA (H = High, L = Low) and vaccination status (V = 118 
vaccinated; NV = Non-vaccinated), as detailed in Table 1. At 3 weeks of age, V piglets 119 
(n=171) were injected IM (neck muscle; needle length: 0.9x25 mm) with 1 mL of Ingelvac 120 
Circoflex (Boehringer Ingelheim; Batch number 309-762B), in the right side of neck. NV 121 
animals (n=166) received the same dose of PBS at the same anatomic location. Animals 122 
from different treatments were comingled in the same pens, both in nurseries and fattening 123 
units. Mortality was recorded through the study.   124 
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During the study period, blood samples from all monitored pigs were subsequently 125 
taken at 7, 12, 18, 22 and 25 weeks of age. Once in the laboratory, blood samples were 126 
allowed to clot and centrifuged at 1500 g for 10 min.  127 
Additionally, animals were weighted at 12 and 25 weeks of age. ADWG was 128 
calculated for the following periods: 2-12, 12-25 and 2-25 weeks of age. ADWG was 129 
calculated as the weight at the last studied time point minus the weight at first selected time 130 
point divided by the days lapsed between both time points.  131 
Treatments, housing, and husbandry procedures were conducted in accordance with 132 
the guidelines of Good Experimental Practices, under the approval of the Ethical and 133 
Animal Welfare Committee of the Universitat Autònoma of Barcelona and Government of 134 
Catalunya (Protocol #DMAH-5796).   135 
 136 
2.3. PCR and quantitative PCR (QPCR)  137 
DNA extracted from serum samples was processed by standard PCV2 PCR and 138 
those yielding positive results were subsequently tested by a QPCR commercial kit (LSI 139 
VetMAX Porcine Circovirus Type 2 - Quantification). Standard PCR results were expressed 140 
as percentage of positive animals. QPCR results and area under the curve (AUC) of viremia 141 
[13] were expressed as log10 PCV2 DNA copies/mL (±SD) for QPCR positive samples.  142 
 143 
2.4. PCV2 antibody detection 144 
Serum samples were tested by a commercial indirect ELISA (INGEZIM, Circo IgG 145 
1.1. PCV. K.1). Mean cut-off for this ELISA tests was set at 0.4 OD following the 146 
manufacturer’s instructions. Results of ELISA were expressed as mean S/P ratio (±SD) and 147 
percentage of seropositive pigs. 148 
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 149 
2.5. Statistical analyses 150 
All statistical analyses were done by SPSS 15.0 software (SPSS Inc., Chicago, IL, 151 
USA). All the parameters assessed were compared at two different levels: 1) between V and 152 
NV piglets, and 2) among H-V, L-V, H-NV and L-NV groups. Descriptive statistics were 153 
used to summarize categorical and quantitative variables. Normality of distribution of the 154 
examined quantitative variables was evaluated by Shapiro Wilk´s and Levene tests. Body 155 
weight and ADWG were compared using an un-paired T-test. The Chi-square or Fischer 156 
exact test was applied to evaluate the proportion of positive and negative animals by ELISA, 157 
PCR and the mortality among these four groups. Data on ELISA S/P ratios, PCV2 viral 158 
load and AUCs were assessed with a non-parametric Mann–Whitney test. The significance 159 
level was set at 0.05. 160 
 161 
3. Results 162 
3.1. Clinical findings 163 
No PCV2-SD-like clinical signs were observed throughout the trial (3 to 25 weeks 164 
of age). Percentage of dead pigs was 3.2% (3 out of 93), 2.5% (2 out of 78), 2.6% (2 out of 165 
76) and 4.4% (4 out of 90) for H-V, L-V, H-NV, L-NV animals, respectively (P>0.05). 166 
Specific causes for such mortality were not investigated. In addition, 10 animals were 167 
excluded from the study because of losing their ear tags. 168 
 169 
3.2. Comparisons between vaccinated and non-vaccinated pigs 170 
3.2.1. PCR and QPCR 171 
PCV2 was firstly detected in both treatments at 18 weeks of age (Fig.1). Percentage 172 
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of PCV2 PCR positive pigs as well as mean PCV2 load in serum was significantly lower at 173 
18, 22 and 25 weeks of age in V than NV pigs. PCV2 load AUC was significantly higher (P 174 
<0.05) in NV (6.0±1.3 log10 PCV2 DNA copies/mL) than in V (4.8±1.1 log10 PCV2 DNA 175 
copies/mL) animals. 176 
 177 
3.2.2. Antibody dynamics 178 
 At 7, 12 and 18 weeks of age, percentage of seropositive pigs was significantly 179 
higher in V group than in their NV counterparts (Fig. 2). Mean ELISA S/P values were 180 
significantly higher (P<0.05) in V compared to NV pigs from 7 to 18 weeks of age. From 181 
that moment onwards, the ELISA S/P ratios from V pigs were significantly lower (P<0.05) 182 
than those of NV animals. 183 
 184 
3.2.3. Body weight and ADWG  185 
No statistical differences were found in the body weight between V and NV piglets 186 
from the beginning to the end of the study (Table 2). ADWG was significantly higher 187 
(P<0.05) in V compared to NV during the 12-25 and 2-25 week-periods; specifically, V 188 
animals gained 33 and 17g per day more than NV pigs, in the respective periods. 189 
 190 
3.3. Comparisons among vaccinated and non-vaccinated pigs with low and high ELISA S/P 191 
values 192 
 3.3.1. PCR and QPCR 193 
A significantly (P<0.05) lower number of PCV2 PCR positive pigs was observed in 194 
L-V compared to NV groups at 18, 22 and 25 weeks of age and in H-V group compared to 195 
NV groups at 22 and 25 weeks of age (Fig 3). Between the two V groups, statistical 196 
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significant differences were only found at 22 weeks of age (higher number of PCV2 PCR 197 
positive pigs in the H-V group).  198 
A significantly (P<0.05) lower PCV2 load in serum was observed in L-V compared 199 
to the both NV groups at 18 and 22 weeks of age and in H-V pigs compared to the NV 200 
groups at 22 and 25 weeks of age. No statistical differences were found between L-V and 201 
H-V groups throughout the study.  202 
The AUC of viral load in H-V (5.1±1.3 log10 PCV2 DNA copies/mL) and L-V 203 
(4.5±1.0 log10 PCV2 DNA copies/mL) groups was significantly lower (P<0.05) than in H-204 
NV (5.8±1.3 log10 PCV2 DNA copies/mL) and L-NV (6.2±1.3 log10 PCV2 DNA 205 
copies/mL). However, no statistical differences were found between H-V and L-V (P=0.09) 206 
and between H-NV and L-NV (P=0.11) AUC of viral loads. 207 
 208 
3.3.2. Antibody dynamics  209 
Statistically significant differences in percentage of ELISA positive animals among 210 
the 4 groups were observed at 7, 12 and 18 weeks of age (Fig 4A). At 7 weeks of age, the 211 
lowest (P<0.05) percentage of seropositive pigs was observed in L-NV, followed by the one 212 
in L-V group. Five weeks later, L-NV group showed still a significantly lower (P<0.05) 213 
percentage of ELISA positive pigs than the other three groups. At that point, while L-V and 214 
H-NV had similar percentage of seropositive pigs, H-V group showed the highest rate of 215 
ELISA positive pigs. At 18 weeks of age, the dynamics changed since the highest (P<0.05) 216 
percentage of ELISA positive animals was observed in L-V animals.  217 
A sharp decrease (up to 12 weeks of age) of ELISA S/P values was observed in both 218 
H groups (Fig 4B). On the contrary, in the L groups the decrease in S/P values was seen 219 
until 7 weeks of age. At that point, whereas L-V pigs showed a progressive increase of 220 
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ELISA S/P values, a flat line from 7 to 18 weeks of age was observed in L-NV ones. 221 
Afterwards, all groups experienced an increase of ELISA S/P ratios being significantly 222 
higher (P<0.05) in both NV groups than their V counterparts. At the two latter sampling 223 
points, L-V pigs had significantly lower (P<0.05) ELISA S/P ratios than H-V ones. 224 
 225 
3.3.3. Body weight and ADWG 226 
At 2 and 12 weeks of age, no significant differences were observed in body weight 227 
among the 4 groups (Table 2). At 25 weeks of age, L-NV showed the lowest body weight, 228 
being significantly lower (P<0.05) when compared to V pigs. 229 
L-V and L-NV pigs showed the highest and the lowest ADWG values, respectively, 230 
in both periods 12-25 and 2-25 weeks. Statistically significant differences were observed 231 
between L-V and NV groups for the period 12-25 weeks and between V and L-NV for the 232 
period 2-25 weeks.  233 
 234 
4. Discussion 235 
 The effect of MDA levels at vaccination age was assessed on ADWG as primary 236 
outcome. The initial hypothesis was that the higher the MDA at vaccination timing, the 237 
lower the ADWG. However, such hypothesis was not confirmed since a potential 238 
detrimental effect of MDA on ADWG was not evident. Although L-V animals grew 2 and 239 
18 g per day more than H-V ones in the 2-25 and 12-25 week periods, such differences 240 
were not statistically significant. Besides, virological and serological parameters were also 241 
studied. In the present study, pigs vaccinated with low MDA seemed to take more benefit of 242 
the treatment than their counterparts with high MDA, since they had a lower PCV2 243 
infection rate (at 22 weeks of age), lower AUC of viral load and showed an earlier 244 
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seroconversion (evident at 12 weeks of age). These latter results would be in accordance 245 
with those previously published studies [5, 6, 8] in which the interference of high MDA 246 
titres at the moment of vaccination with the humoral response elicited by the vaccine was 247 
demonstrated. It is worthy to highlight, however, that vaccination was able to overcome 248 
such interference since statistically significant differences were seen between H-V vs H-NV 249 
animals in terms of infection rate at 22 and 25 weeks of age and mean ELISA S/P ratios at 250 
18 weeks of age.  251 
 The specific reason by which MDA affected PCV2 virological and serological 252 
parameters but not ADWG remains unknown. Recent data in non-vaccinated pigs have 253 
demonstrated that the higher the AUC of viral load, the lower the ADWG [13]. This 254 
situation applied in the present work when comparing the V and NV groups, but the 255 
scenario is more complex when studying existing subpopulations in terms of low and high 256 
MDA at vaccination. Under the scenario of low MDA levels, V animals had significantly 257 
lower AUC and significantly higher ADWG than their NV counterparts; on the contrary, in 258 
a high MDA level context, V animals had a significantly lower AUC but similar ADWG 259 
than NV ones. In addition, the numeric but non-significant ADWG differences between L-260 
V and H-V may suggest that, if occurring, interference of MDA with ADWG would be seen 261 
only in those animals with extremely high MDA levels. This hypothesis would be 262 
supported by the fact that in the present and in Haake et al. [10] studies, the best (although 263 
no significantly different) productive performances were seen when vaccination was 264 
applied in the presence of low MDA titres. Indeed, in the present study, the 10 animals with 265 
the highest MDA titres (>2.4 ELISA S/P titres) at the moment of vaccination, coming all of 266 
them from vaccinated sows, grew 52 g/day less than the rest of the vaccinated animals (n= 267 
151, with average ELISA S/P value of 1.23±0.65) (data not shown). According to Pileri et 268 
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al. [12], these >2.4 S/P values would be equivalent to >17 log2 immunoperoxidase 269 
monolayer assay (IPMA) titres. In fact, the MDA titres producing interference on the 270 
humoral response to vaccination has been established around 8-10 log2 IPMA titres [7], 271 
being 14 log2 IPMA the result of the highest dilution of the IPMA test routinely performed 272 
[14]. In consequence, 17 log2 IPMA titres would be an extremely high MDA titre, probably 273 
not very frequently found under field conditions. Therefore, if these high MDA titres are 274 
present in a very small proportion of animals, the economic relevance of such putative 275 
interference would be presumably low or negligible in most of the cases.  276 
These very high antibody titres were “artificially” created by means of vaccinating a 277 
proportion of the sows. This action was aligned with the need of a sufficient number of 278 
piglets with the highest MDA levels possible to achieve the objective of this study. It cannot 279 
be ruled out that both humoral and cellular immunity linked to the colostrum intake from 280 
these sows might have exerted certain effect on the obtained results. However, such effect 281 
is not very likely, since MDA levels reached the lowest S/P ratios around 12 weeks of age, 282 
while evidence of PCV2 infection started at 18 weeks of age. In consequence, it is difficult 283 
to believe that, at those ages, MDA exerted an effect on virus dynamics. Moreover, the 284 
antibody evolution of piglets with high antibody values coming from vaccinated and non-285 
vaccinated sows were very similar (data not shown), reinforcing the notion that sow 286 
vaccination did not apparently bias the obtained results. The potential effect of sow 287 
vaccine-derived cellular immunity on piglet vaccine response was not known. According to 288 
the results obtained in field and experimental studies [8, 15], such effect is probably short-289 
lasting and not likely to interfere on piglet vaccine intake. Moreover, it is also unlikely that 290 
such immunity would exert effects on pigs that were infected in the growing-finishing 291 
phase. However, cell-mediated immunity was not measured in the present study and no 292 
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conclusions can be drawn. 293 
 294 
5. Conclusion  295 
Under the conditions of this study, vaccination at 3 weeks of age was able to 296 
efficiently control PCV2 infection, reduce PCV2 viral load, increase the serological 297 
response against the infection and improve ADWG when compared to NV pigs. Although 298 
the pigs with the best growth performance were those with low ELISA S/P values at the 299 
moment of vaccination, presence of high MDA values at that moment did not interfere in 300 
the ADWG of pigs. Evident detrimental effects of MDA on ADWG were exclusively 301 
observed in a minimal number of pigs with extremely high MDA at the time of vaccination, 302 
which probably represents a negligible population of animals under field conditions.  303 
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Table 1 
 Piglet distribution according to PCV2 MDA level at 2 weeks of age, PCV2 vaccination 
(V= vaccinated; NV= Non-vaccinated) and sow treatment (V= vaccinated; NV= Non-
vaccinated). 
 
PIGLETS Sow treatment   
Level of S/P ratio at  
2 weeks of age 
Treatment NV V Total 
High S/P ratio 
(> 1.44, equivalent to 
>log2 13 IPMA 
values*) 
NV 6 70 76 
V 13 80 93 
Low S/P ratio 
 (< 0.96, equivalent  
to <log2 10 IPMA 
values*) 
NV 75 15 90 
V 59 19 78 
Total 153 184 337 
Tables
Table 2 1 
 Body weight (mean, [kg±SD]) at different weeks of age and average daily weight gain (ADWG, [g ±SD]) for different week 2 
intervals. Different letters within a sampling point mean statistically significant differences (p<0.05). 3 
 4 
 5 
 
 
Body weight (kg) 
 
ADWG (g) 
 
Weeks of age 2 12 25 
Period 
(weeks) 
2-12 12-25 2-25 
G
ro
u
p
s NV 2.4±0.5
a
 27.1±5.8
 a
 98.3±13.9
 a
 
G
ro
u
p
s 324.5±72.1
 a
 774.5±111.7
 a
 570.9±81.5
 a
 
V 2.4±0.5
 a
 26.8±4.9
 a
 101.0±12.8
 a
 321.4±60.9
 a
 807.4±107.6
 b
 587.5±75.3
 b
 
 
        
G
ro
u
p
s 
H-NV 2.5±0.5
 a
 28.0±5.8
 a
 100.9±12.8
 ab
 
G
ro
u
p
s 
336.5±72.3
 a
 792.3±90.9
 a
 586.1±74.7
 ab
 
L-NV 2.4±0.5
 a
 26.3±5.7
 a
 96.2±14.6
 a
 314.4±70.8
 a
 759.7±125.2
 a
 558.2±85.0
 a
 
H-V 2.4±0.5
 a
 27.5±5.2
 a
 101.3±13.0
 b
 329.9±655.3
 a
 799.0±112.7
 ab
 586.8±81.7
 b
 
L-V 2.4±0.6
 a
 26.1±4.4
 a
 100.5±12.6
 b
 311.7±54.1
 a
 816.8±101.5
 b
 588.3±67.8
 b
 
Tables
Figure captions 1 
Fig.1. PCR and QPCR results for V and NV. Percentage of PCV2 PCR positive pigs (bars 2 
and left Y axis) and log10 PCV2 DNA viral loads (mean± SD) (lines and right Y axis) of 3 
PCR positive pigs in V and NV groups at the six sampling time points, respectively. In the 4 
table, different low-case letters within a sampling point mean statistically significant 5 
differences in the percentage of PCR positivity between V and NV pigs (P<0.05); different 6 
capital letters within a sampling point mean statistically significant differences in PCV2 7 
DNA load in serum between V and NV pigs (P<0.05). 8 
  9 
Fig. 2. ELISA results for V and NV. Percentage of ELISA positive pigs (bars and left Y axis) 10 
and PCV2 ELISA S/P ratio (mean± SD) (lines and right Y axis) values and in the six 11 
sampling points for both V and NV pigs, respectively. Different low-case letters in the table 12 
within a sampling point mean statistically significant (P<0.05) differences in percentage of 13 
ELISA positivity between V and NV animals; different capital letters within a sampling 14 
point mean statistically significant differences in ELISA S/P values among the 4 groups 15 
(P<0.05). 16 
  17 
Fig. 3. PCR and QPCR results for H-NV, L-NV, H-V and L-V. Percentage of PCV2 PCR 18 
positive pigs (bars and left Y axis) and log10 PCV2 DNA loads (mean± SD)  (lines and right 19 
Y axis) of PCR positive pigs in H-NV, L-NV, H-V and L-V groups at the six sampling 20 
times, respectively. In the table, different low-case letters within a sampling point mean 21 
statistically significant differences in the percentage of PCR positivity among the 4 groups 22 
(P<0.05); different capital letters within a sampling point mean statistically significant 23 
differences in PCV2 DNA load in serum among the 4 groups (P<0.05). 24 
Figures captions
 25 
Fig. 4.  A. ELISA positive percentage for H-NV, L-NV, H-V and L-V. Percentage of ELISA 26 
positive pigs at the six sampling points for H-NV, L-NV, H-V and L-V pigs. Different low-27 
case letters in the table within a sampling point mean statistically significant (P<0.05) 28 
differences in percentage of ELISA positive pigs among the 4 groups. B. ELISA S/P ratio 29 
for H-NV, L-NV, H-V and L-V. PCV2 ELISA S/P ratio (mean± SD) values at the six 30 
sampling points for H-NV, L-NV, H-V and L-V pigs. Different low-case letters in the table 31 
within a sampling point mean statistically significant (P< 0.05) differences in ELISA S/P 32 
values among the 4 groups.  33 
 34 
Fig. 1.  
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